Syrosingopine

Clinical data
Trade names	Singoserp
ATC code	C02LA09 (WHO) (combination with diuretics)
Identifiers
IUPAC name Methyl (3β,16β,17α,18β,20α)-18-({4-[(Ethoxycarbonyl)oxy]-3,5-dimethoxybenzoyl}oxy)-11,17-dimethoxyyohimban-16-carboxylate
CAS Number	84-36-6
PubChem CID	6769
ChemSpider	6511
UNII	PPG46JF0EG
KEGG	D01659
CompTox Dashboard (EPA)	DTXSID9023629
ECHA InfoCard	100.001.388
Chemical and physical data
Formula	C35H42N2O11
Molar mass	666.724 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCOC(=O)Oc1c(cc(cc1OC)C(=O)O[C@@H]2C[C@@H]3CN4CCc5c6ccc(cc6[nH]c5[C@H]4C[C@@H]3[C@@H]([C@H]2OC)C(=O)OC)OC)OC
InChI InChI=1S/C35H42N2O11/c1-7-46-35(40)48-31-26(42-3)12-18(13-27(31)43-4)33(38)47-28-14-19-17-37-11-10-22-21-9-8-20(41-2)15-24(21)36-30(22)25(37)16-23(19)29(32(28)44-5)34(39)45-6/h8-9,12-13,15,19,23,25,28-29,32,36H,7,10-11,14,16-17H2,1-6H3/t19-,23+,25-,28-,29+,32+/m1/s1 Key:ZCDNRPPFBQDQHR-SSYATKPKSA-N

Syrosingopine is a drug, derived from reserpine. It is used (since about 1960) to treat hypertension.^[1][2]

Research

A combination of the diabetes drug metformin and syrosingopine killed tumor cells in blood samples from leukemia patients, while it did not damage blood cells in samples from healthy patients. The combination of metformin and syrosingopine also reduced or eliminated tumors in mice with malignant liver cancer.^[3] The drugs interfere with the cancer cells' glucose (i.e. energy) supply and utilization. Cancer cells have much higher energy requirements than normal cells, making them vulnerable when there is a reduction in the available energy supply. Syrosingopine inhibits the degradation of sugars within the cells.^{[4][medical citation needed]}